Emerging in the arena of excess body fat therapy, retatrutide represents a unique method. Different from many existing medications, retatrutide functions as a dual agonist, at once affecting both glucagon-like peptide-1 (GLP-1) and glucose-sensitive insulinotropic polypeptide (GIP) receptors. The concurrent activation encourages several helpful eff